ViviGen® demonstrated successful fusion and healing in 86% of 135 high-risk patients undergoing primary and revision foot and ankle procedures.

Effective despite comorbidities:
ViviGen Cellular Bone Matrix contributed to successful fusion even in patients with comorbidities, such as diabetes, thyroid disease, and/or alcohol abuse, which put them at higher risk for nonunion. In the arthrodesis cohort, only smoking and Charcot foot were associated with a lower rate of fusion. Comorbidities in the ORIF cohort did not compromise bony healing.

Fusion and healing rates comparable to autograft:
The overall fusion rate in 113 high-risk patients with comorbidities in the arthrodesis cohort was 85.84%. The overall bony healing rate in 22 high-risk patients with comorbidities in the ORIF cohort was 86.36%. These fusion and healing rates are comparable to reported rates using autograft.

No significant difference between primary and revision surgery:
Primary arthrodesis procedures resulted in an 85.56% rate of successful fusion versus 86.96% for revision. Primary ORIF procedures resulted in an 82.35% rate of successful bony healing versus 100% for revision. There was no statistically significant difference between primary and revision surgery (p>0.05). Published literature suggests poorer outcomes following revision surgery.

Fusion and Healing Rates in Arthrodesis and ORIF using ViviGen in High-Risk Patients